Microvascular Angiopathic Consequences of COVID-19

Frontiers in Cardiovascular Medicine

Muhammad F. Masood¹  Linda J. Schulte¹  Margaret Nalugo²  Mohamed A. Zayed³ 

[1] Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States;Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States;Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States;Division of Molecular Cell Biology, Washington University School of Medicine, St. Louis, MO, United States;Department of Biomedical Engineering, McKelvey School of Engineering, Washington University, St. Louis, MO, United States;Veterans Affairs St. Louis Health Care System, St. Louis, MO, United States;

关键词: COVID-19;    micovascular disease;    angiopathy;    cardiac dysfunction;    vascular thrombosis;   

DOI  :  10.3389/fcvm.2021.636843

来源: Frontiers

【 摘 要 】

The coronavirus disease-2019 (COVID-19) pandemic has rapidly spread across the world. The disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan, China in December, 2019. Ever increasing data is continuing to emerge about the impact of COVID-19 on cardiovascular tissue and other organ system. Clinical features associated with COVID-19 suggest that endothelial cell dysfunction and microvascular thrombosis are to a large extent contributing to resultant multi-organ complications. This review is aimed at highlighting the critical aspects associated with COVID-19 and its presumed microvascular angiopathic consequences on the cardiovascular system leading to multi-organ dysfunction.

【 授权许可】

CC BY